Lixte Biotechnology (LIXT) Competitors $1.35 +0.09 (+7.48%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT vs. MIRA, GOVX, NRSN, GLYC, IPA, LPTX, CLRB, COCP, ME, and SPRBShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include MIRA Pharmaceuticals (MIRA), GeoVax Labs (GOVX), NeuroSense Therapeutics (NRSN), GlycoMimetics (GLYC), ImmunoPrecise Antibodies (IPA), Leap Therapeutics (LPTX), Cellectar Biosciences (CLRB), Cocrystal Pharma (COCP), 23andMe (ME), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. MIRA Pharmaceuticals GeoVax Labs NeuroSense Therapeutics GlycoMimetics ImmunoPrecise Antibodies Leap Therapeutics Cellectar Biosciences Cocrystal Pharma 23andMe Spruce Biosciences MIRA Pharmaceuticals (NASDAQ:MIRA) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation. Is MIRA or LIXT more profitable? MIRA Pharmaceuticals' return on equity of -337.44% beat Lixte Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -337.44% -280.58% Lixte Biotechnology N/A -5,562.77%-130.48% Do analysts prefer MIRA or LIXT? MIRA Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 1,220.75%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe MIRA Pharmaceuticals is more favorable than Lixte Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Lixte Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in MIRA or LIXT? 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 14.8% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has better valuation and earnings, MIRA or LIXT? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$11.98M-$0.52-2.04Lixte BiotechnologyN/AN/A-$5.09M-$1.59-0.85 Does the MarketBeat Community prefer MIRA or LIXT? MIRA Pharmaceuticals received 3 more outperform votes than Lixte Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformMIRA PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo VotesLixte BiotechnologyN/AN/A Does the media refer more to MIRA or LIXT? In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 2 mentions for MIRA Pharmaceuticals and 0 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.00 beat MIRA Pharmaceuticals' score of -0.29 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment MIRA Pharmaceuticals Neutral Lixte Biotechnology Neutral Which has more volatility & risk, MIRA or LIXT? MIRA Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. SummaryMIRA Pharmaceuticals beats Lixte Biotechnology on 10 of the 15 factors compared between the two stocks. Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.24M$6.63B$5.43B$7.75BDividend YieldN/A3.20%5.44%4.31%P/E Ratio-0.787.1322.2418.28Price / SalesN/A238.37389.36101.44Price / CashN/A65.6738.2034.62Price / Book6.126.256.654.16Net Income-$5.09M$142.48M$3.21B$247.58M7 Day Performance12.25%7.49%5.49%5.88%1 Month Performance-0.59%-6.38%-4.63%-3.60%1 Year Performance-58.55%-1.20%17.67%4.86% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte BiotechnologyN/A$1.35+7.2%N/A-61.7%$4.24MN/A-0.784MIRAMIRA Pharmaceuticals2.4479 of 5 stars$0.89+2.9%$14.00+1,473.0%+14.3%$14.96MN/A-1.592GOVXGeoVax Labs2.4708 of 5 stars$1.07+4.9%$14.20+1,227.1%-35.1%$14.81M$3.95M-0.1910News CoverageGap UpNRSNNeuroSense Therapeutics0.2732 of 5 stars$1.08+1.9%N/A-25.4%$14.76MN/A-1.6910News CoverageGap UpGLYCGlycoMimetics1.9321 of 5 stars$0.22+10.0%N/A-86.5%$14.32M$10,000.000.0050Analyst ForecastNews CoverageIPAImmunoPrecise Antibodies1.9359 of 5 stars$0.46+6.0%$4.00+775.1%-62.0%$14.20M$24.00M-0.5980LPTXLeap Therapeutics1.2985 of 5 stars$0.34+5.2%$4.92+1,341.8%-88.1%$14.07MN/A-0.1840CLRBCellectar Biosciences2.2016 of 5 stars$0.29+5.5%$12.50+4,144.5%-89.8%$13.57MN/A-0.1710COCPCocrystal Pharma1.9158 of 5 stars$1.33+3.9%$7.00+426.3%-2.7%$13.53MN/A-0.7210News CoverageGap DownME23andMe0.433 of 5 stars$0.50-35.3%$9.40+1,787.6%-94.7%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeSPRBSpruce Biosciences3.0177 of 5 stars$0.31+8.0%$2.50+695.2%-80.1%$12.99M$7.10M-0.3320Positive NewsGap Up Related Companies and Tools Related Companies MIRA Alternatives GOVX Alternatives NRSN Alternatives GLYC Alternatives IPA Alternatives LPTX Alternatives CLRB Alternatives COCP Alternatives ME Alternatives SPRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIXT) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LIXT Stock Free LIXT Stock Alerts